JP2008545780A - 有機化合物 - Google Patents

有機化合物 Download PDF

Info

Publication number
JP2008545780A
JP2008545780A JP2008515811A JP2008515811A JP2008545780A JP 2008545780 A JP2008545780 A JP 2008545780A JP 2008515811 A JP2008515811 A JP 2008515811A JP 2008515811 A JP2008515811 A JP 2008515811A JP 2008545780 A JP2008545780 A JP 2008545780A
Authority
JP
Japan
Prior art keywords
phenyl
methylamino
oxo
dihydro
propionamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008515811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545780A5 (cg-RX-API-DMAC7.html
Inventor
チェン・チュオリアン
マーク・ジー・パレルモ
スシル・ケイ・シャーマ
トロイ・スミス
クリストファー・エス・ストラウブ
ルン−ミン・ディ・ワン
ワン・ヤピン
リー・ザウェル
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2008545780A publication Critical patent/JP2008545780A/ja
Publication of JP2008545780A5 publication Critical patent/JP2008545780A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
JP2008515811A 2005-06-08 2006-06-06 有機化合物 Pending JP2008545780A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68863905P 2005-06-08 2005-06-08
PCT/US2006/021850 WO2006133147A2 (en) 2005-06-08 2006-06-06 Organic compounds

Publications (2)

Publication Number Publication Date
JP2008545780A true JP2008545780A (ja) 2008-12-18
JP2008545780A5 JP2008545780A5 (cg-RX-API-DMAC7.html) 2009-07-23

Family

ID=37052743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008515811A Pending JP2008545780A (ja) 2005-06-08 2006-06-06 有機化合物

Country Status (11)

Country Link
US (2) US7989441B2 (cg-RX-API-DMAC7.html)
EP (1) EP1902065A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008545780A (cg-RX-API-DMAC7.html)
KR (1) KR20080022092A (cg-RX-API-DMAC7.html)
CN (1) CN101193908B (cg-RX-API-DMAC7.html)
AU (1) AU2006255084A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0611922A2 (cg-RX-API-DMAC7.html)
CA (1) CA2610396A1 (cg-RX-API-DMAC7.html)
MX (1) MX2007015419A (cg-RX-API-DMAC7.html)
RU (1) RU2007147959A (cg-RX-API-DMAC7.html)
WO (1) WO2006133147A2 (cg-RX-API-DMAC7.html)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512879A (ja) * 2012-02-27 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｍａｃミメチックスとしての６−アルキニルピリジン
JP2015527315A (ja) * 2012-07-13 2015-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗増殖性ベンゾ［ｂ］アゼピン−２−オン
JP2015528483A (ja) * 2012-09-19 2015-09-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ２−オキソ−２，３，４，５−テトラヒドロ−１ｈ−ベンゾ［ｂ］ジアゼピン及びがんの治療におけるその使用
JP2018162256A (ja) * 2012-11-30 2018-10-18 サンフォード−バーンハム メディカル リサーチ インスティテュート アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
US10300074B2 (en) 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
KR20200006120A (ko) * 2017-05-17 2020-01-17 데날리 테라퓨틱스 인크. 화합물, 조성물 및 방법
JP2020502089A (ja) * 2016-12-09 2020-01-23 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 化合物、組成物および方法
JP2023541475A (ja) * 2020-09-17 2023-10-02 ノバルティス アーゲー Ｓｐｐｌ２ａ阻害剤としての化合物及び組成物
US12678509B2 (en) 2019-11-08 2026-07-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (IAP) protein antagonists

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
EA012810B1 (ru) 2005-02-25 2009-12-30 Тетралоджик Фармасеутикалс Димерные ингибиторы ингибиторов белков апоптоза (iap)
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
WO2007101347A1 (en) * 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
MX2009000824A (es) 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CA2670726A1 (en) 2006-12-07 2008-06-19 Novartis Ag 6-oxo-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases
BRPI0720049A2 (pt) * 2006-12-07 2014-01-07 Novartis Ag Derivados de piridina utilizados como inibidores de xiap
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
US8871111B2 (en) * 2008-03-18 2014-10-28 Ngk Insulators, Ltd. Piezoelectric/electrostrictive ceramic composition
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
TW201249824A (en) 2011-03-09 2012-12-16 Glaxosmithkline Llc Peptide deformylase inhibitors
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ））
RU2015105561A (ru) 2012-08-09 2016-09-27 Ф. Хоффманн-Ля Рош Аг Замещенные гетероазепиноны
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
CA2925084A1 (en) * 2013-11-18 2015-05-21 F. Hoffmann-La Roche Ag Tetrahydro-benzodiazepinones
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
AR101479A1 (es) 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
EA038950B1 (ru) 2016-05-19 2021-11-12 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения производных 6-алкинил-пиридина
CN106674228B (zh) * 2016-12-09 2018-12-04 河南农业大学 多元杂环化合物及其制备方法和用途
US20230056604A1 (en) 2020-01-20 2023-02-23 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
WO2025061058A1 (en) * 2023-09-18 2025-03-27 Ascentage Pharma (Suzhou) Co., Ltd. Novel compounds as iap antagonists

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0656785A (ja) * 1991-04-18 1994-03-01 Imperial Chem Ind Plc <Ici> 複素環アミド類
WO1995003289A1 (en) * 1993-07-26 1995-02-02 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
JPH08225586A (ja) * 1995-02-22 1996-09-03 Fujisawa Pharmaceut Co Ltd 新規リン酸誘導体、その製造法およびそれを含有する医薬組成物
JP2001500377A (ja) * 1996-09-12 2001-01-16 アイドゥン ファーマシューティカルズ，インコーポレイテッド インターロイキン―１β―転換酵素（ＩＣＥ）／ＣＥＤ―３ファミリーインヒビターを用いたアポトーシスの阻害
JP2002520372A (ja) * 1998-07-15 2002-07-09 ジーピーシー バイオテック インコーポレーテッド 真菌の増殖を阻害するための組成物および方法
WO2003065987A2 (en) * 2002-02-04 2003-08-14 Merck & Co., Inc. Granzyme b inhibitors
WO2004072641A1 (en) * 2003-02-07 2004-08-26 Genentech, Inc. Compositions and methods for enhancing apoptosis
US20040242494A1 (en) * 2003-05-27 2004-12-02 Guy Brenchley Caspase inhibitors and uses thereof
WO2005069894A2 (en) * 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2006010118A2 (en) * 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2006017296A1 (en) * 2004-07-12 2006-02-16 Micron Technology, Inc. Dual panel pixel readout in an imager
JP2008545629A (ja) * 2005-05-18 2008-12-18 アエゲラ セラピューティクス インコーポレイテッド Ｂｉｒドメイン結合化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
BRPI0513310A (pt) 2004-07-12 2008-05-06 Idun Pharmaceuticals Inc análogos de tetrapeptìdeo

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0656785A (ja) * 1991-04-18 1994-03-01 Imperial Chem Ind Plc <Ici> 複素環アミド類
WO1995003289A1 (en) * 1993-07-26 1995-02-02 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
JPH08225586A (ja) * 1995-02-22 1996-09-03 Fujisawa Pharmaceut Co Ltd 新規リン酸誘導体、その製造法およびそれを含有する医薬組成物
JP2001500377A (ja) * 1996-09-12 2001-01-16 アイドゥン ファーマシューティカルズ，インコーポレイテッド インターロイキン―１β―転換酵素（ＩＣＥ）／ＣＥＤ―３ファミリーインヒビターを用いたアポトーシスの阻害
JP2002520372A (ja) * 1998-07-15 2002-07-09 ジーピーシー バイオテック インコーポレーテッド 真菌の増殖を阻害するための組成物および方法
WO2003065987A2 (en) * 2002-02-04 2003-08-14 Merck & Co., Inc. Granzyme b inhibitors
WO2004072641A1 (en) * 2003-02-07 2004-08-26 Genentech, Inc. Compositions and methods for enhancing apoptosis
US20040242494A1 (en) * 2003-05-27 2004-12-02 Guy Brenchley Caspase inhibitors and uses thereof
WO2005069894A2 (en) * 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2006010118A2 (en) * 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2006017296A1 (en) * 2004-07-12 2006-02-16 Micron Technology, Inc. Dual panel pixel readout in an imager
JP2008545629A (ja) * 2005-05-18 2008-12-18 アエゲラ セラピューティクス インコーポレイテッド Ｂｉｒドメイン結合化合物

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512879A (ja) * 2012-02-27 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｍａｃミメチックスとしての６−アルキニルピリジン
JP2015527315A (ja) * 2012-07-13 2015-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗増殖性ベンゾ［ｂ］アゼピン−２−オン
JP2015528483A (ja) * 2012-09-19 2015-09-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ２−オキソ−２，３，４，５−テトラヒドロ−１ｈ−ベンゾ［ｂ］ジアゼピン及びがんの治療におけるその使用
JP2018162256A (ja) * 2012-11-30 2018-10-18 サンフォード−バーンハム メディカル リサーチ インスティテュート アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
US10544188B2 (en) 2012-11-30 2020-01-28 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis protein (IAP) antagonists
US11912786B2 (en) 2012-11-30 2024-02-27 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis protein (IAP) antagonists
US11111270B2 (en) 2012-11-30 2021-09-07 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis protein (IAP) antagonists
US10300074B2 (en) 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
US10864217B2 (en) 2014-06-04 2020-12-15 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
JP7208137B2 (ja) 2016-12-09 2023-01-18 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
JP2020502089A (ja) * 2016-12-09 2020-01-23 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 化合物、組成物および方法
KR20200006120A (ko) * 2017-05-17 2020-01-17 데날리 테라퓨틱스 인크. 화합물, 조성물 및 방법
JP2022174180A (ja) * 2017-05-17 2022-11-22 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
JP7140781B2 (ja) 2017-05-17 2022-09-21 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
US11851433B2 (en) 2017-05-17 2023-12-26 Denali Therapeutics Inc. Compounds, compositions and methods
KR102637541B1 (ko) 2017-05-17 2024-02-15 데날리 테라퓨틱스 인크. 화합물, 조성물 및 방법
JP2020520925A (ja) * 2017-05-17 2020-07-16 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 化合物、組成物および方法
US12678509B2 (en) 2019-11-08 2026-07-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (IAP) protein antagonists
JP2023541475A (ja) * 2020-09-17 2023-10-02 ノバルティス アーゲー Ｓｐｐｌ２ａ阻害剤としての化合物及び組成物
JP7771172B2 (ja) 2020-09-17 2025-11-17 ノバルティス アーゲー Ｓｐｐｌ２ａ阻害剤としての化合物及び組成物

Also Published As

Publication number Publication date
CN101193908B (zh) 2012-04-11
WO2006133147A2 (en) 2006-12-14
WO2006133147A3 (en) 2007-05-03
RU2007147959A (ru) 2009-07-20
US20090069294A1 (en) 2009-03-12
CN101193908A (zh) 2008-06-04
EP1902065A2 (en) 2008-03-26
US7989441B2 (en) 2011-08-02
CA2610396A1 (en) 2006-12-14
BRPI0611922A2 (pt) 2010-10-05
US20110281845A1 (en) 2011-11-17
AU2006255084A1 (en) 2006-12-14
MX2007015419A (es) 2008-02-21
KR20080022092A (ko) 2008-03-10

Similar Documents

Publication Publication Date Title
US7989441B2 (en) Organic compounds
CN100384819C (zh) 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂
EP2882740B1 (en) Iap antagonists
KR100504449B1 (ko) 세포 유착 억제제
KR100892185B1 (ko) Ｉａｐ 억제제
EP2917218B1 (en) Macrocyclic compounds for inhibition of inhibitors of apoptosis
EP0997474B1 (en) Antithrombotic agents
JPH07196658A (ja) 縮合多環式ラクタム含有化合物
WO1995003277A1 (en) Novel pyrrolidine derivative
JP2011102312A (ja) テトラペプチド類似体
JP2009545613A (ja) Ｉａｐ阻害剤として有用なｓｍａｃペプチド模倣物
EP2897949A1 (en) Iap antagonists
JP2008504240A (ja) Ｃ型肝炎インヒビターペプチド類似体
CA2211890A1 (en) Fibrinogen receptor antagonists
JPH10510511A (ja) 成長ホルモンの放出を促進するジペプチド類
EP2861581A1 (en) Iap antagonists
US5494897A (en) Endothelin antagonistic peptide
KR20010023656A (ko) 골 대사성 질환의 치료를 위한 아르기닌 모의체를함유하는 펩타이드, 그의 제조 방법, 및 이를 함유한 약제
EP1819332B1 (en) Pyrrolopyridine-2-carboxylic acid amides
KR20070119088A (ko) 아팝토시스 단백질 억제제 (ｉａｐ) 조절제로서의2-아미노카르보닐 치환된 피페라진 또는 디아자-시클릭화합물
Pulka et al. Synthesis of 4-amino-3-oxo-tetrahydroazepino [3, 4-b] indoles: new conformationally constrained Trp analogs
JPH05271187A (ja) ピロリジン誘導体又はその薬学的に許容される塩
HK1213543B (en) Dimeric compounds
MXPA99007603A (en) Antitromboti agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090604

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120619